# Company presentation Full year 2019












### SOL Group at a glance

- Founded in 1927, is an Italian based multinational company present in 29 countries with more of 4,400 people employed.
- Two core, separated but integrated and synergic business areas: Technical Gas sector (production, applied research and marketing of pure, medical and industrial gases) and Home-Care service sector (supply of medical products and medical assistance services as well as equipment for home care therapy).
- Two recent businesses: Hydro Energy and Biotechnology.
- Strong results and sound balance sheet:
  - Over 904 millions € of Total Group revenues in FY2019 (+8.5% FY2018);
  - Over 56% of international revenues in 2019 (vs 23.7% in 2000)
  - 6.9% sales CAGR in the last 10 years;
  - 23.4% of EBITDA margin in 2019;
  - 0.503 of Debt/Equity ratio; 1.38 of Debt/EBITDA ratio;
    - Dividend policy: 31% average dividend pay out ratio over the last 10 years.



## **SOL Group – Geographic Presence**





## The major Italian Chemicals Companies (2019)

(millior	n Euro)	World sales	Italian sales	(millio	n Euro)	World sales	Italian sales
1°	Versalis	4.119	3.110	21°	Fluorsid Group	328	193
2°	Gruppo Mapei	2.774	837	22°	Gruppo Desa	284	284
3°	Gruppo Bracco	1.199	749	23°	Novamont	269	268
4°	Radici Group	1.091	649	24°	Alfa Parf Group	244	44
5°	Gruppo SOL	904	395	25°	Reagens	233	107
6°	COIM Group	842	422	26°	Sadepan Chimica	223	157
7°	Polynt Group (*)	833	625	27°	FACI Group	221	90
8°	P & R Group	821	568	28°	Indena/Gr. IdB Holding	216	177
9°	Gruppo Intercos	712	410	29°	3V Partecip. Industriali	210	150
10°	Gruppo SIAD	700	512	30°	Gruppo Metlac	201	201
11°	Italmatch Chemicals	595	144	31°	Sabo	178	178
12°	Gruppo Colorobbia	571	210	32°	Mirato Group	167	167
13°	Gruppo Sapio	551	508	33°	Davines	163	163
14°	Gruppo Sodalis	550	331	34°	Gr. Durante/TLD Holding	158	157
15°	Gruppo Aquafil	549	182	35°	Istituto Ganassini	151	93
16°	Gruppo Lamberti	510	240	36°	Valagro	148	118
17°	Esseco Group	465	255	37°	Gruppo Silvateam	147	106
18°	FIS	463	447	38°	Gruppo Coswell	142	142
19°	Gruppo Sipcam-Oxon	455	261	39°	Renner	134	44
20°	Gruppo Zobele te: companies with majority of Italian capita	415 al; values refer to ch	69 emical sales (no ph	40° narmaceutical s	Paglieri sales)	133	133

Source: Federchimic

## The Technical Gases Business





### The Technical Gases Business

SOL Group operates in the technical gases business throughout the brand SOL

#### **Production and distribution of Gases**

A complete range of industrial gas (both atmospheric and non-atmospheric): medicinal, pure and special gases

- ◆ Oxygen
- Nitrogen
- Argon
- Hydrogen
- Carbon dioxide
- Acetylene
- Nitrous oxide
- Gas mixtures

- Ultra high purity gases
- Medical gasesGaseoushelium
- ◆ Liquid helium
- Refrigerating gases

- Electronics gases
- Ammonia
- ◆ Combustible gases
- ♦ LNG
- ♦ Sulfur oxide SO2
- Nitric oxide NO

### Supply of plants, equipment, services and consultancy

Research, design, and construction of:

- Industrial gas production facilities
- Plant and equipment for gas utilization
- Services and consultancy

- Equipment for medical applications
- Equipment for cryogenic applications
- Deep freezing tunnels
- Oxygen burners
- Ozonisers

- Medical air plants
- On-site plants
- Welding machines and equipment



### **Technical Gases Business**

Technical gases business (M€)	FY2019	FY2018	YoY
Sales	443	432	+ 2.5%
EBITDA	77	78	- 1.6%
EBITDA %	17.3%	18.0%	- 0.7
Investments	53	55	- 4.2%

- In 2019 the division invested over the12% of its revenues.
- 4.1% sales CAGR over the last 10 ys.







### **Technical Gases business**

#### **Market characteristics**


- Resilient and growing market
- Margin protected thanks to high entry barriers
- Limited economic cycle demand dependence of each sales area
  - Broad variety and diversification of end-markets and applications
- Medium/long term contracts
- Local presence as a key factor


#### SOL

- High diversification of sales area:
  - . More than 50,000 clients served;
  - More than 90 different applications for technical gases
- Long term contracts with customers:
  - Gas pipeline: up to 15 years;
  - Compressed gases: up to 5 years;
  - Cryogenic liquid gases: up to 3 years
- Strong local presence:
  - 26 countries, 38 sources and primary transformation plants, 49 secondary transformation plants.



## Primary Sources & Production Sites (ASU, ...)






## The Home Care Business





### **The Home Care Business**

- In the second half of the eighties, SOL seized a new market diversification opportunity by entering into the Home-Care service sector, synergical with the technical gas sector.
- The Group works through the VIVISOL Group, which supplies technologically advanced home care services to patients for the treatment of chronic pathologies.
- VIVISOL manages the complete patient care from the delivery of medical equipment and drugs, performed by specialized home care professionals, to the provision of qualified medical and nursing services, as well as tele-monitoring services and emergency management.
- The company operates in Brazil, Turkey and in 14 leading countries in Europe, with over 70 offices employing over 2.500 employees and serving more than 500.000 patients daily.





### **The Home Care Business**

### Home care respiratory assistance

- Long term oxygen therapy
- Mechanical ventilation therapy
- Assistance to patients undergoing oxygen therapy during travels (VIVITRAVEL)
- Diagnosis and treatment of sleep disorder conditions

#### Other home care assistance

- Home care artificial nutrition
- Integrated home care services
- Remote monitoring and diagnosis of respiration conditions
- Palliative Care




### **Home Care Business**

Hone Care business	FY2019	FY2018	YoY
(M€)			
Sales	493	431	+ 14.3%
EBITDA	135	109	+ 23.5%
EBITDA %	27.3%	25.3%	+ 2.0
Investments	50	44	+ 13.3%

- VIVISOL was able to grow 14,3% in 2019, with an EBITDA margin higher than 27%.
- The Group is continuing to invest significantly in this business.







### **Home Care Business**




### **Key growth drivers:**

- Aging population demographics
- Restructuring of Health Care Systems through de-hospitalization and home care
- Developments in portable medical technologies
- Better quality of life for Patients at home
- Increasing of respiratory and chronic pathologies







## **Home Care Business**





## The Hydro Energy Business





## **The Hydro Energy Business**

- Leveraging on its core business development in the Eastern Europe, SOL entered into the Hydro-Energy sector.
- The industrial gas sector, is one of the most energy intensive one. This characteristic supported the Group decision to invest in the Hydro-Energy sector in order to enjoy synergies with its Industrial Gases Business.





Currently the company owns and operates 5 hydro-electric power plants in Slovenia (about 50 Million KWh/year), 2 plants in Albania (about 25 Million KWh/year); 4 plants in Macedonia (about 35 Million KWh/year); 4 plants in Bosnia (about 6 Million KWh/year).




## The Biotechnology Business





## The Biotechnology Business

- SOL Group is active in supplying biotechnological equipment and services to hospitals, clinics and laboratories (cryobanks, cellfactories, cryomanagement, cryotransportation)
- With BIOTECHSOL and CRYOLAB is active in the area of tissue and stem cells banking and biological materials transportation.
- With DIATHEVA is active in drug discovery and drug delivery (recombinant monoclonal antibodies), molecular diagnostic, GMP production of recombinant proteins
- With PERSONAL GENOMICS is active in genetic analysis service and genetic testing research and development.















## SOL Group: 30 years Turnover (1989-2019)





## **SOL Group: consolidated results** (2009 – 2019)




### 10 years net profit and dividend growth



#### **DPS - Dividend Yield**





**10Y AVERAGE PAY-OUT RATIO 31%** 



## **International Expansion**

### 10 years sales outside Italy 2009-2019



## **SOL** is focused on its international expansion:

- The Group started its operations in Italy where it currently has 13 primary production sites.
- In 2019 the Group is present in 29 countries.
- In 2019 the non-domestic sales exceeded the Italian sales (56.3% / 43.7%).



## **63 JV & ACQUISITION** (1999-2019)


Co	ompany	Year of acquisition	Division
ABILITY TEAM	Germany	1999	Home Care
BARTOLO	Italy	1999	Technical Gases
PROMKOOP	Bulgaria	1999	Technical Gases
SOL-INA	Croatia	1999	Technical Gases
FRANCE OXYGENE	France	2000	Home Care
HGT	Greece	2000	Technical Gases
TGT	Bosnia	2001	Technical Gases
ZEUS	Greece	2001	Technical Gases
BEHRINGER	Italy	2002	Technical Gases
ENERGETIKA	Slovenia	2002	Technical Gases
HOSPITAL SERVICE	Italy	2002	Home Care
TGP	Bosnia	2002	Technical Gases
ELOMED	Germany	2003	Home Care
IL POINT	Italy	2004	Home Care
OXYMED	Germany	2004	Home Care
MEDIZIN SERVICE	Germany	2006	Home Care
MEDIZIN TECHNIK	Germany	2006	Home Care
JULIA GAS	Italy	2007	Technical Gases
RESMED	Austria	2008	Home Care
BOESCH	Germany	2009	Home Care
JLV	Spain	2009	Home Care
DOLBY	UK - Scotland	2010	Home Care
FRODITHYA	Greece	2010	Home Care
MEDES	Italy	2010	Technical Gases
OSSIGEN GAS	Italy	2010	Technical Gases
SICGILSOL	India	2010	Technical Gases
GTH	Romania	2011	Technical Gases
HYDROENERGY	Albania	2011	Technical Gases
DIATHEVA	Italy	2012	Biotech
MEDICAL SYSTEM	Italy	2012	Technical Gases
VIVISOL TK	Turkey	2012	Home Care
СТВ	Germany	2014	Technical Gases

	Year of acquisition	Division	
France	2014	Home Care	
Germany	2014	Technical Gases	
Italy	2014	Technical Gases	
Slovenia	2014	Home Care	
Italia	2015	Biotech	
Morocco	2015	Technical Gases	
Brazil	2015	Home Care	
Germany	2015	Home Care	
India	2015	Technical Gases	
Potugal	2015	Home Care	
Ireland	2016	Technical Gases	
Germany	2016	Home Care	
Bosnia	2016	Technical Gases	
Ireland	2017	Home Care	
Turkey	2017	Technical Gases	
Italy	2017	Biotech	
Turkey	2017	Home Care	
Italy	2017	Technical Gases	
Switzerland	2017	Home Care	
Italy	2017	Technical Gases	
Italy	2018	Technical Gases	
Italy	2018	Home care	
Poland	2018	Home care	
Poland	2018	Home care	
Germany	2018	Home care	
Germany	2019	Home care	
Brazil	2019	Home care	
Brazil	2019	Home care	
Brazil	2019	Home care	
Brazil	2019	Home care	
Switzerland	2019	Home Care	
	Germany Italy Slovenia Italia Morocco Brazil Germany India Potugal Ireland Germany Bosnia Ireland Turkey Italy Turkey Italy Italy Switzerland Italy Italy Italy Italy Bosnia Ireland Turkey Italy Turkey Italy Ita	France         2014           Germany         2014           Italy         2014           Slovenia         2014           Italia         2015           Morocco         2015           Brazil         2015           Germany         2015           India         2015           Potugal         2015           Ireland         2016           Germany         2016           Bosnia         2016           Ireland         2017           Turkey         2017           Italy         2018           Italy         2018           Italy         2018           Poland         2018           Poland         2018           Germany         2019           Brazil         2019           Brazil         2019           Brazil         2019           Brazil         2019	



## Capital Expenditures & Acquisition (2009-2019)


### 10 years of Capex & M&A on sales 2009-2019



### High annual investments

- The Group every year invest about 16% of its revenues;
- The Sol business require a high level of investments for long term growth options;
  - In 2019 almost the 61% of the Group investments in CAPEX (without M&A) was made outside Italy.

## Shareholding information and market price



Source: Borsa Italiana

### **Outstanding Shares**

- 90.700.000 ordinary shares
- par value: 0,52

### **Shareholding Structure**

- Fumagalli and Annoni families 60%
- Main Institutional Investors:
  - Tweedy Brown
  - Azvalor



## SOL Group Consolidated Income Statement

(thousands Euro)			
	31.12.19	31.12.18	2019/ 2018
Net turnover	904,313	833,513	+ 8.5%
Total revenues	926,858	852,873	+ 8.7%
	102.5%	102.3%	
Added value	416,422	369,802	+ 12.6%
	46.0%	44.4%	
EBITDA	211,307	186,933	+ 13.0%
	23.4%	22.4%	
EBIT	88,660	89,654	- 1.1%
	9.8%	10.8%	
CDOLID			

## SOL Group Consolidated Income Statement

(Thousands Euro)
------------------

ilousullus Euroj				
	31.12.	19	31.12.	18
		%		%
Net turnover	904,313	100.0	833,513	100.0
Other revenues	8,883	1.0	7,729	0.9
Internal work capitalized	13,662	1.5	11,630	1.4
Total revenues	926,858	102.5	852,873	102.3
Raw materials	212,870	23.5	206,202	24.7
Services	272,233	30.1	247,851	29.7
Stocks	1,752	0.2	(5,240)	(0.6)
Other costs	23,580	2.6	34,258	4.1
Total costs	510,436	56.4	483,070	58.0
Added value	416,422	46.0	369,802	44.4
Labour costs	205,115	22.7	182,870	21.9
EBITDA	211,307	23.4	186,933	22.4



## SOL Group Consolidated Income Statement

(Thousands Euro)

nousanus Euroj				
	31.12.3	19	31.12.1	<b>18</b>
		%		%
EBITDA	211,307	23.4	186,933	22.4
Depreciation & Amortization	105,472	11.7	88,606	10.6
Other provisions	7,066	0.8	7,733	0.9
Operating income recurring	98,769	10.9	90,594	10.9
Non recurring (Income)/Charges	10,109	1.1	940	0.1
EBIT	88,660	9.8	89,654	10.8
Net financial	(8,459)	(0.9)	(8,485)	(1.0)
PBT	80,201	8.9	81,169	9.7
Taxes	27,784	3.1	27,203	3.3
Net profit from ongoing operations	52,417	5.8	53,966	6.5
Minorities	(3,079)	(0.3)	(2,086)	(0.3)
NET PROFIT	49,338	5.5	51,880	6.2
EPS	0.544		0.572	



## SOL Group Consolidated Balance Sheet

(Thousands Euro)			<b> </b>		
	31.12.19	31.12.18		31.12.19	31.12.18
Assets			Liabilities		
Net fixed assets	534.1	475.4	Shareholder's equity	560.6	527.9
Other fixed assets	184.7	142.9	Minorities	19.4	18.1
Cash and liquid assets	169.3	129.3	Financial debts	400.8	331.3
Inventory	49.5	50.7	Other non current liabilities	21.9	20.6
Net receivables	280.1	280.0	Payables	108.5	107.3
Other current assets	36.7	33.8	Other current liabilities	143.3	106.9
Total assets	1,254.4	1,112.2	Total liabilities	1,254.4	1,112.2



# SOL Group Net Financial Position

(Thousands Euro)

	31.12.19	31.12.18
Cash and cash at bank	169,326	129,350
Securities	4,147	2,404
Loans - current portion	(55,327)	(53,126)
Leases - current portion	(14,338)	(549)
Due to shareholders	(2,415)	(2,000)
Other financial receivables - current portion	3,920	3,269
Other financial liabilities - current portion	(2,034)	(1,893)
Short term liquidity	103,279	77,454
Investments securities	1,055	773
Loans - long term portion	(361,937)	(325,753)
Leases - long term portion	(34,686)	(320)
Due to shareholders	(1,107)	(2,900)
Other financial receivables - long term portion	3,681	3,697
Other financial liabilities - long term portion	(2,190)	(1,500)
Medium long term debt	(395,184)	(326,002)
TOTAL NET LIQUIDITY	(291,905)	(248,548)











